Navigation Links
Antigens in Biological Technology

ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens

... an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its DepoVax(TM) delivery platform to develop ...

Medicago succesfully expresses VLP antigen for A H1N1 strain

... production allowing for immediate access to the antigens of emerging influenza strains. Current influenza ... system which produces recombinant vaccine antigens in non-transgenic plants. This technology has ... strikes and to supply large volumes of vaccine antigens to the world market. Additional information about ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... be designed to bind to well established target antigens of conventional monoclonal antibodies, but also ... Officer Dr. Patrick A. Baeuerle. "Many target antigens for cancer therapy are released by cancer cells ... BiTE antibody suggests that high levels of shed antigens may not pose a limitation for the anti-tumor ...

ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery

... liposomes, adjuvants and oil. DepoVax(TM) enhances the immunogenicity of antigens in general, and can be used to dramatically enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a ...

Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose

... using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer ... first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at ...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

... has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against antigens licensed from its collaborative partners. About Morphotek ...

Medicago initiates work on Swine Flu strain

... using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer ... first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at ...

IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis

... for more than 15 years. We have built a large portfolio of vaccine antigens that may be useful for both prevention and treatment of leishmaniasis," ... candidates, we are delighted to provide two of our most advanced candidate antigens to a research institution with such a long track-record in vaccine ...

Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks

... elicits a robust immune response because it delivers immune-alerting antigens directly to the lining of the nasal mucosa, where the virus first enters ... of oil, water, alcohol and antimicrobial surfactant together with antigens from specific pathogens. The nasally delivered vaccines easily penetrate ...

Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur

... Maxygen will transfer to sanofi pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second generation ... the four virus subtypes were recombined, with the goal of creating novel antigens that could produce a protective immune response against all four virus ...

GenVec Reports Second Quarter 2009 Financial Results

... support the Company's malaria vaccine program. This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development. Other Developments GenVec strengthened its cash position by raising $6.0 million from a ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... cell transplantation. GVHD is an inflammatory disease initiated by T cells in the donor graft that recognize histocompatibility and other tissue antigens of the host, and is mediated by a variety of effector cells and inflammatory cytokines. GVHD presents in both acute and chronic forms. The symptoms ...

Abbott HIV Test Demonstrates Earlier Disease Detection

... at the American Association for Clinical Chemistry annual meeting shows that an assay developed by Abbott for simultaneous detection of both HIV antigens and antibodies reduced the detection window by zero to nine days in this study compared to HIV antibody-only assays. Earlier detection was shown on ...

American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals

... of IgE antibodies in a small blood sample. They are automated and accurate -- similar to other blood serum diagnostic tests. Their test antigens are standardized -- enabling reliable and reproducible test results. Siemens and The Walt Disney Company Form Alliance ...

Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test

... to experts.(i) Bacteria can cause fatal reactions, especially in immune-compromised patients. The Verax PGD(R) test, a rapid immunoassay, targets antigens found on the surface of a wide spectrum of common bacteria known to be pathogenic to humans in high concentrations. "Bacterial contamination ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... This TB data demonstrated that vaccines utilizing the L.E.A.P.S. vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune responses that would be expected to be protective against tuberculosis and have the potential to treat swine and other H1N1 ...

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

... and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The antibodies within the company's pipeline are targeted against antigens licensed from its collaborative partners. Through its technology and collaborations, the company remains committed to bringing a new treatment option ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. Morphotek will be responsible for validating targets discovered through genomic research provided by HGS, generating and ...

Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting

... domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion's SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor ...

ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats

... and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT's DepoVax(TM) vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats. "Dr. Les Nagata and his research team at DRDC are leaders in ...

Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7

... peptides in a spatially defined conformation. These molecules have proven to be superior in defining discontinuous epitopes. More importantly, CLIPS antigens have now proven to yield antibodies that recognize the protein they are derived from. Pepscan Therapeutics is a privately owned company based ...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

... to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "The rapid commercialization of our late-stage compounds ...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

... lines by T lymphocytes redirected with a MCSP/CD3-bispecific single-chain antibody construct is independent of the expression of tumor-associated antigens gp100, MART-1, tyrosinase and NY-ESO1. AACR Annual Meeting 2009, abstract no. 4152; to be presented in session 'Immunology 6' on April 21, 2009, 1:00 ...

ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria

... and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in Maryland, USA. The research collaboration involves formulating NIAID antigens in DepoVax(TM), IVT's vaccine enhancement system, and exploring potential vaccines for HIV and malaria. "NIAID is a world leader in the study of ...

PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies

... form of skin cancer. PDS Biotechnology's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen-presenting cells of the immune system. Simultaneously it acts as a strong immune system activator (adjuvant) without the inflammatory ...

OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China

... has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen ...

Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza

... based on VLPs can overcome many of the limitations of traditional influenza vaccines by offering highly immunogenic, strain-specific recombinant antigens that can be produced economically and at large scale. VLPs are self-assembling particles that can be made in cell culture, avoiding the need to rely ...

Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants

... donor T cells that are transferred along with stem cells from donated blood or bone marrow (the graft) stage an immune response to the "foreign" antigens in the tissues of many organs of the host's (patient's) body. These anti-host donor T cells attack the tissues and can cause major organ failure or ...

Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today

... and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these ...

Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics

... such as hepatitis C and B, and human papillomavirus (HPV). The company also sells genetic tests for cystic fibrosis and tests for human leukocyte antigens (HLA) that are used to establish tissue compatibility in organ transplants. Innogenetics recently received CE marking for its first assay on its new ...

ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform

... well suited for large scale distribution and long term storage. DepoVax(TM) vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations. DepoVax(TM) vaccines are also easy to administer by health care practitioners, an ...

Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine Initiative

... diseases. Hawaii Biotech has developed a proprietary protein production platform that has application to the production of proteins for use as antigens in infectious disease vaccines. In addition, to its work on a dengue vaccine, the company is also developing vaccines for West Nile virus and ...

Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results

... its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the research, human/animal diagnostics, and ...

Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress

... will apply its proprietary technologies to enhance the pharmacologic properties of monoclonal antibodies developed by HGS that specifically target antigens discovered by HGS. Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional payments including ...

Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Human Genome Sciences and Xencor Announce Antibody Collaboration

... humanization and optimization technologies to enhance the pharmacologic properties of monoclonal antibodies developed by HGS that specifically target antigens discovered by HGS. (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) "The priority focus of HGS continues to be the rapid ...

Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

... products target EpCAM, which has recently also been identified as a cancer stem cell marker and is one of the most frequently over-expressed cancer antigens known. A growing body of evidence implicates a functional role for EpCAM in diverse cellular processes such as signaling, cell migration, ...
Other Contents
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible ... lives of patients, according to a newly published report. Surviving Mesothelioma has more ... article. , The authors of the new paper focus on several types ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
Other TagsOther Tags